Insider Selling: Lexeo Therapeutics (NASDAQ:LXEO) CFO Sells $20,214.47 in Stock

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) CFO Louis Edward Tamayo sold 4,117 shares of the stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $4.91, for a total transaction of $20,214.47. Following the completion of the transaction, the chief financial officer owned 92,907 shares in the company, valued at $456,173.37. This represents a 4.24% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Louis Edward Tamayo also recently made the following trade(s):

• On Wednesday, July 1st, Louis Edward Tamayo sold 4,641 shares of Lexeo Therapeutics stock. The shares were sold at an average price of $4.49, for a total transaction of $20,838.09.

Lexeo Therapeutics Stock Performance

LXEO traded up $0.44 during trading on Wednesday, reaching $5.37. 941,872 shares of the company’s stock were exchanged, compared to its average volume of 952,662. The company’s fifty day moving average price is $4.70 and its 200-day moving average price is $5.56. Lexeo Therapeutics, Inc. has a fifty-two week low of $3.99 and a fifty-two week high of $10.99. The firm has a market capitalization of $440.61 million, a PE ratio of -4.67 and a beta of 1.46.

Lexeo Therapeutics (NASDAQ:LXEO) last posted its quarterly earnings results on Wednesday, August 12th. The company reported ($0.30) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.01). Research analysts forecast that Lexeo Therapeutics, Inc. will post -1.18 earnings per share for the current fiscal year.

Institutional Trading of Lexeo Therapeutics

Large investors have recently made changes to their positions in the company. Mirae Asset Global Investments Co. Ltd. grew its stake in Lexeo Therapeutics by 69.9% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,547 shares of the company’s stock valued at $35,000 after acquiring an additional 1,459 shares during the period. Bank of America Corp DE raised its position in shares of Lexeo Therapeutics by 6.1% during the third quarter. Bank of America Corp DE now owns 28,279 shares of the company’s stock worth $188,000 after purchasing an additional 1,626 shares during the period. California State Teachers Retirement System raised its position in shares of Lexeo Therapeutics by 123.7% during the fourth quarter. California State Teachers Retirement System now owns 3,884 shares of the company’s stock worth $39,000 after purchasing an additional 2,148 shares during the period. Intech Investment Management LLC lifted its holdings in shares of Lexeo Therapeutics by 19.5% during the 4th quarter. Intech Investment Management LLC now owns 14,188 shares of the company’s stock valued at $141,000 after purchasing an additional 2,317 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. lifted its holdings in shares of Lexeo Therapeutics by 25.6% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 11,893 shares of the company’s stock valued at $118,000 after purchasing an additional 2,427 shares in the last quarter. Institutional investors own 60.67% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have weighed in on LXEO. Chardan Capital raised Lexeo Therapeutics to a “strong-buy” rating in a research note on Tuesday, July 28th. Weiss Ratings upgraded Lexeo Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, August 13th. JPMorgan Chase & Co. lowered their price target on Lexeo Therapeutics from $12.00 to $9.00 and set an “overweight” rating for the company in a research note on Thursday, June 25th. Finally, Wall Street Zen downgraded shares of Lexeo Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Saturday. Two equities research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Buy” and an average target price of $18.75.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to developing novel, precision‐designed therapies for central nervous system disorders. The company’s research platform leverages advanced medicinal chemistry to create next‐generation psychedelic-inspired compounds aimed at treating a range of mental health conditions, including anxiety, depression and substance use disorders.

The company’s pipeline features proprietary synthetic molecules engineered to target specific neural pathways while improving safety and tolerability profiles over traditional treatments.